Medicinal application of corylin

A technology of psoralenin and bone fat, applied in the field of natural medicine

Inactive Publication Date: 2017-05-10
CHINA PHARM UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there are no reports about the treatment or prevention of hyperlipidemia, h

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal application of corylin
  • Medicinal application of corylin
  • Medicinal application of corylin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] In order to study the effect of psoralening on the mouse model induced by high fat, use C57BL mice, SPF grade, male, body weight (20 ± 2) g, and randomly divide them into two groups, the first group of 12 is the normal group, Give normal feed, and the remaining mice (40) are divided into 4 groups, give high-fat feed (feed calorie 19.4% protein, 20.6% carbohydrate, 60% fat) free to eat and drink. The matrix, lovastatin group (30mg / kg), psoralenin low concentration group (15mg / kg) and psoralenin high concentration group (30mg / kg) were administered respectively. Continuous feeding for 6 weeks.

[0047] The configuration method of Bakuchining: dissolve with 0.5% CMC-Na solution.

[0048] Observation indicators:

[0049] a general condition of the animal

[0050] The experimental animals were exposed to light for 12 hours and night for 12 hours, free to eat and drink, and the animals were in normal state during the experiment.

[0051] b Observe food intake and body weig...

Embodiment 2

[0056] Effects of Bakuzhining on Animal Models of Hyperlipidemia

[0057] Experimental animals and methods:

[0058] C57BL mice, SPF grade, male, body weight (20 ± 2) g, were randomly divided into two groups, the first group of 12 was the normal group, given normal feed, and the remaining mice (40) were divided into 4 groups, given With high-fat feed (feed caloric 19.4% protein, 20.6% carbohydrate, 60% fat) ingest and drink freely. The matrix, lovastatin group (30mg / kg), psoralenin low concentration drug (15mg / kg) and psoralenin high concentration group (30mg / kg) were administered respectively. Continuous feeding for 6 weeks. Blood collection, execution, and liver tissue collection.

[0059] Observation indicators:

[0060] a general condition of the animal

[0061] The experimental animals were raised in the SPF animal room, with 12 hours of light and 12 hours of darkness, free to eat and drink, and the animals were in normal state during the experiment.

[0062] b blood ...

Embodiment 3

[0080] Effects of Bakuzhining on Animal Models of Hyperglycemia

[0081] In order to study the effect of psoralening on diabetes, the classic high-fat-induced diabetic mouse model was used in this experiment. C57BL mice, SPF grade, male, body weight (20±2) g, were randomly divided into two groups, the first group 12 Only, be normal group, give normal feed, all the other mice (40) are divided into 4 groups, give high-fat feed (feed caloric 19.4% protein, 20.6% carbohydrate, 60% fat) ad libitum intake, drinking water. The matrix, lovastatin group (30mg / kg), psoralenin low concentration drug (15mg / kg) and psoralenin high concentration group (30mg / kg) were administered respectively. Continuous feeding for 6 weeks. Fasting overnight after the end of administration, fasting blood glucose, glucose tolerance and insulin tolerance were measured. Glucose tolerance test method: mice were fasted overnight, and mice were orally administered with blood glucose 2g / kg at 0, 15, 30, 60, 90, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to corylin compositions for treating or preventing any one or more of hyperlipemia, hyperglycemia, nonalcoholic fatty liver and diabetes mellitus type 2; the compositions can be prepared into medicines, health foods or functional foods; excipients or carriers used for the compositions are excipients or carriers such as diluents, disintegrating agents and lubricating agents which are commonly used in the field of pharmacy or food.

Description

technical field [0001] The invention belongs to the field of natural medicines, and discloses the medical use of psoralening. The invention discloses the use of psoralening for preventing or treating hyperlipidemia, hyperglycemia, non-alcoholic fatty liver and type 2 diabetes. Background technique [0002] Diabetes mellitus is a metabolic disease characterized by hyperglycemia caused by defects in insulin secretion and / or its biological function. Metabolic diseases seriously endanger human health, and active prevention and treatment of diabetes has become a major social public health problem. [0003] Western medicine often uses diet, exercise therapy sulfonylureas, biguanides, thiazolidinediones, α-glucosidase inhibitors, repaglinide, insulin, etc. to treat type II diabetes, and only thiazolidinediones can Improve insulin resistance. While the patient is being treated with western medicine, complications such as arteriosclerosis, coronary heart disease, and hypertension c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61P3/10A61P3/06A61P1/16A23L33/10
CPCA23V2002/00A61K31/352A23V2200/30A23V2200/328
Inventor 徐晓军李会军郑祖国周亚萍李萍
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap